Dynavax Technologies Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Dynavax Technologies stock.
View analyst ratings for Dynavax Technologies or view top-rated stocks.

3 equities research analysts have issued 1 year price targets for Dynavax Technologies' stock. Their DVAX stock forecasts range from $19.00 to $28.00. On average, they expect Dynavax Technologies' stock price to reach $23.50 in the next year. This suggests a possible upside of 83.5% from the stock's current price.
View analysts' price targets for Dynavax Technologies or view top-rated stocks among Wall Street analysts.

Dynavax Technologies' stock was trading at $14.07 at the beginning of the year. Since then, DVAX shares have decreased by 9.0% and is now trading at $12.81.
View the best growth stocks for 2022 here.

Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Dynavax Technologies.

Dynavax Technologies Co. (NASDAQ:DVAX) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by $0.02. The biopharmaceutical company had revenue of $113.99 million for the quarter, compared to analyst estimates of $117.76 million. Dynavax Technologies had a net margin of 23.12% and a trailing twelve-month return on equity of 87.36%. During the same quarter in the prior year, the business posted $0.01 EPS.
View Dynavax Technologies' earnings history.

13 employees have rated Dynavax Technologies CEO Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among Dynavax Technologies' employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of DVAX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (13.09%), State Street Corp (6.73%), BlackRock Inc. (6.17%), Chicago Capital LLC (4.69%), Vanguard Group Inc. (4.63%) and Fisher Asset Management LLC (2.78%). Company insiders that own Dynavax Technologies stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Victory Capital Management Inc., BNP Paribas Arbitrage SA, Jane Street Group LLC, Fisher Asset Management LLC, Group One Trading L.P., BlackRock Inc., and Rhenman & Partners Asset Management AB. Company insiders that have sold Dynavax Technologies company stock in the last two years include Andrew A F Hack, David F Novack, Justin Burgess, Robert Janssen, and Ryan Spencer.
View insider buying and selling activity for Dynavax Technologies or view top insider-selling stocks.

DVAX stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Edmond DE Rothschild Holding S.A., Bank of Montreal Can, Renaissance Technologies LLC, Goldman Sachs Group Inc., Federated Hermes Inc., Bank of America Corp DE, and Blair William & Co. IL.
View insider buying and selling activity for Dynavax Technologies or or view top insider-buying stocks.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DVAX stock can currently be purchased for approximately $12.81.

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.62 billion and generates $439.44 million in revenue each year. The biopharmaceutical company earns $76.71 million in net income (profit) each year or $0.549990 on an earnings per share basis.

Dynavax Technologies employs 311 workers across the globe.

Dynavax Technologies was founded in 1996.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for Dynavax Technologies is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at [email protected], or via fax at 510-848-1327.